Mobile

A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sympt...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001452-39

A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and tolerability of long-term treatment with YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder

Critère d'inclusion

  • Symptoms of Overactive Bladder

Liens